News and Trends 7 Feb 2023 AAHI bags $9.9M to develop nasal spray influenza RNA vaccine The Access to Advanced Health Institute (AAHI) has been awarded a project agreement worth up to $9.9 million through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA) to develop a prototype intranasal bivalent influenza RNA vaccine candidate. The candidate will be based on AAHI’s self-amplifying RNA (saRNA) platform, which targets both pandemic A(H5N1) […] February 7, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2023 Endogena Therapeutics retinitis pigmentosa treatment gets FDA fast track designation The US Food and Drug Administration (FDA) has designated the investigation of Endogena Therapeutics’ EA-2353 for the treatment of retinitis pigmentosa (RP) as a fast track development program. Fast track is a process designed to enable patients to benefit earlier from new drugs for serious conditions. Endogena Therapeutics’ EA-2353 takes a novel, small-molecule approach and […] February 7, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 6 Feb 2023 The biggest private biotech investments in January 2023 The companies Asimov, BioRay Pharmaceuticals and Colossal Biosciences bagged the biggest biotech investments in January 2023. Around the world, synthetic biology players and firms developing treatments for hormonal disorders attracted the biggest funding rounds. 2023 began with a bang in terms of biotech funding, and there are signs of stabilization in biotech stocks after two […] February 6, 2023 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Feb 2023 Genoscience Pharma receives orphan drug designation for hepatocellular carcinoma drug Genoscience Pharma has announced that its lead candidate, ezurpimtrostat, a PPT-1 (Palmitoyl Protein Thioesterase-1) inhibitor, has been granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC). ODD qualifies ezurpimtrostat for a potential seven years of market exclusivity after approval. The FDA’s ODD program provides […] February 3, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Feb 2023 Crown Bioscience acquiring Indivumed’s service business and biobank Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has entered into an agreement to acquire the IndivuServ business unit of Indivumed GmbH. A share purchase agreement (SPA) between was executed in December, 2022, and subject to customary closing adjustments, the transaction is expected to close in April 2023. Indivumed […] February 2, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Feb 2023 Recurv Pharma receives funding for cancer therapy development Recurv Pharma Inc. is receiving up to $24 million in funding from TVM Capital Life Science through its TVM Life Science Innovation II SCSp fund. Recurv Pharma plans to develop a novel taxane therapy to treat solid tumors to the proof-of-concept stage. The U.S. based biotech firm is the eighth early-stage or project-focused company (PFC) […] February 2, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2023 How can patients have access to the latest science? Innovation in cancer research is happening at an accelerated rate, but the current healthcare system is not equipped to ensure patients can quickly access the latest science. There is a disconnect between treatment innovation and clinical practice. Most cancer patients are seen at community hospitals and treated by generalist oncologists, and data shows that a […] February 1, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2023 Stemline Therapeutics’ breast cancer treatment approved The Menarini Group, an Italian pharmaceutical and diagnostics company, says that the U.S. Food and Drug Administration (FDA) has approved ORSERDU for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline Therapeutics, a wholly-owned subsidiary […] January 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2023 Stargardt disease treatment gets FDA fast track Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation (FTD) for MCO-010. MCO-010 is an ambient-light activatable multi-characteristic opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for the treatment of Stargardt disease to […] January 31, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2023 Abbisko Therapeutics receives breakthrough therapy designation for CSF-1R inhibitor Abbisko Therapeutics Co., Ltd. has announced that its CSF-1R inhibitor Pimicotinib has been granted the breakthrough therapy designation from the FDA for the treatment of tenosynovial giant cell tumor (TGCT) patients that are not amenable to surgery. The designation approval is based on results from the phase Ib clinical trial of TGCT cohort for Pimicotinib. […] January 31, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jan 2023 Aldevron launches type-V CRISPR Nuclease Aldevron, which develops and manufactures plasmid DNA, RNA and proteins for the biotech industry, has launched Eureca-V Nuclease, the wild-type MAD7 CRISPR Type-V nuclease, licensed from Inscripta, at Research Grade, with GMP to follow. Aldevron’s launch at Advanced Therapies Week of Eureca-V Nuclease expands the toolkit of available CRISPR nucleases for therapeutic, diagnostic, and agricultural […] January 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jan 2023 New drug could replace current standard for treating brain cancer Glioblastoma (GBM) is a WHO grade IV brain tumor with dismal prognosis. Although post-surgical radiation chemotherapy combined with temozolomide is the standard line of treatment, GBM cells surviving radiotherapy contribute to tumor progression and recurrence even more aggressively. Researchers have now unveiled the mechanism of radioresistance in glioblastoma cells, identifying therapeutic targets to overcome radioresistance. […] January 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email